Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesUp-regulation of mir-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
Cancer Research, 08/18/09
Li Y et al. - In a study to compare the expression of miRNAs between gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer (PCa)cells and investigate whether treatment of cells with "natural agents" could affect expression of miRNAs, these results provide experimental evidence that 3,3'-diindolylmethane (DIM) and isoflavone could function as miRNA regulators leading to the reversal of epithelial-to-mesenchymal transition (EMT) phenotype, which is likely to be important for designing novel therapies for PCa.
Methods- Expression of miRNAs was compared between gemcitabine-sensitive and gemcitabine-resistant PCa cells and it was investigated whether treatment of cells with "natural agents" [3,3'-diindolylmethane (DIM) or isoflavone] could affect the expression of miRNAs.
- The expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells, which showed EMT characteristics such as elongated fibroblastoid morphology, lower expression of epithelial marker E-cadherin, and higher expression of mesenchymal markers such as vimentin and ZEB1.
- Reexpression of miR-200 by transfection studies or treatment of gemcitabine-resistant cells with either DIM or isoflavone resulted in the down-regulation of ZEB1, slug, and vimentin, which was consistent with morphologic reversal of EMT phenotype leading to epithelial morphology.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Cancer Management and Research, 11/05/09
Today in Stomach/GI...keeping you current
Receive free subspecialty "5-minute updates" via email
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09
Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin
Journal of Viral Hepatitis, 11/09/09
Proton Pump Inhibitors and Pain
Pain Physician, 11/25/09
Sponsor
Article Search
Sponsor